Clinical Trials Browser

Acute Kidney Injury × Plasma cell × Clear all

NCT06549634 2026-02-27

Biomarkers of AKI in Patients Receiving Daratumumab

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT06483139 2025-11-19

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT02358980 2025-06-25

KEEPER

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT00120263 2025-03-25

Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma

Phase NA Completed

GenitourinaryPlasma cell

Multiple Myeloma, Neoplasms, Plasma Cell, Acute Kidney Injury

NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

GenitourinaryPlasma cell

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT05429515 2022-06-23

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

Phase 4 Not yet recruiting

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury